Name: 7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference
Start: 2024-06-20
End: 2024-06-21
Location: Boston, USA

WHAT TO EXPECT

Updates in development of ADC’s and Bispecific Ab’s
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
Biomarkers and Personalized Medicine in IO
CAR-T Cell therapy, TCR Based-Cell Therapy
Tumor microenvironment and Oncolytic Viruses

Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
Find out new case studies of immune-oncology projects in development
Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
Explore the latest platforms and technologies on the market for development
Discuss the best tool for your research in immune-oncology
Share your work and achievements with your industry peers in the Poster Session

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

Monoclonal and Bispecific Antibodies
Cell Therapy
Immune Checkpoint Inhibitors

CONFERENCE AGENDA

Registration	08:15 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
Keynote Presentation - Anchored Immunotherapy: The Next Generation of Local Immuno-Oncology Howard Kaufman, President and Chief Executive Officer, Ankyra Therapeutics	09:00 - 09:30
ADC drug and its applications Siamak Tabrizi, Senior Scientist, Immunitas Therapeutics	09:30 - 10:00
Reserved Slot for Gold Sponsor	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Reserved Slot for Silver Sponsor	11:15 - 11:45
SUPLEXA therapeutic cells, a clinically derisked cell therapy platform with unique mechanisms of action for treating solid cancers Frank Borriello, Founder and CEO, Alloplex Biotherapeutics	11:45 - 12:15
Reserved for Sponsor Presentation	12:15 - 12:45
Innovative Preclinical Models for Investigating Tumor-Immune Interactions	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Preliminary results of a Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors. Roger Waltzman, Chief Medical Officer, Indaptus Therapeutics	14:15 - 14:45
Novel mRNA-based Immunotherapy Vaccines	14:45 - 15:15
Oncolytic viruses in the era of Checkpoint Blockade	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Challenges and Opportunities in Validating Preclinical Models for Immuno-Oncology Drug Development	16:30 - 17:00
Panel Discussions - Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30

Registration	08:15 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
Challenges and Opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination Rakesh Dixit, CEO, Bionavigen	09:00 - 09:30
ProtoNKTM Cells from Pluripotent Stem Cells: Therapeutics for All Patients Shi-Jiang (John) Lu, President and CEO, HebeCell Corporation	09:30 - 10:00
Solution Provider Presentation (Reserved for Gold Sponsor)	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Solution Provider Presentation (Reserved for Silver Sponsor)	11:15 - 11:45
Translational approach in developing right IO therapy	11:45 - 12:15
Development of new generation DNA vaccines	12:15 - 12:45
Combination Strategies to Overcome Resistance to Anti-PD-1/PD-L1 Therapies	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Future opportunities in clinical development of ICI’s	14:15 - 14:45
The Intersection of Immunology and Oncology: Advancing Targeted Therapy Paradigms	14:45 - 15:15
Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care	15:15 - 15:45
Closing Remarks from the Chairperson	15:45 - 15:45